Category

News Brief

Harness Pheromones for Sustainable Pest Control

"Without some method of treatment, about 12% of crops globally would be lost to plant parasitic nematodes,” says Karl Cameron Schiller, co-founder and chief operating officer of bio-tech startup Pheronym. To combat these pests, Schiller and his team are developing non-toxic pesticide solutions that pose fewer risks to the environment.

Heat Brings Out Antioxidants, Increases Red in Tomatoes

Turn up the heat, and get more nutrition from your tomato, University of Florida researchers say. Furthermore, when you buy a tomato, it will be about as red as it can be, thanks to the UF/IFAS methods deployed for the study.

Algae Used As Superfood for Space Travel

Dr. Andrew Mark Settles, UF/IFAS horticultural science professor, is taking part in research designed to grow spirulina, a type of algae that hopes to provide food for long term space travel.

Ology Bioservices Signs Built-to-Suit Lab Space, Adding 43,000 Square Feet to Headquarters

Avison Young facilitated a 42,500-square-foot lease agreement between Concept Companies and Ology Bioservices, a UF startup and UF Innovate | Sid Martin Biotech alum, for a new built-to-suit lab space on the heels of a federal government contract for the company to expand production capabilities, including vaccines and therapeutics for COVID-19 once finalized.

Century 22 Solutions Joins Creek Technologies Company’s OASIS Team

UF Innovate | The Hub resident company Century 22 Solutions LLC (C22) formally announced that it joined with Creek Technologies Company's (CreekTech's) team pursuing opportunities under the General Services Administration (GSA) for the agency's One Acquisition Solution for Integrated Services (OASIS) Small Business (SB) Pool 1 Government-Wide Acquisition Contract (GWAC).

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases

UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures.